Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (401-410 of 635) with videos related to

Pageof 64
Sort By:
Journal of the American Heart Association|October 30, 2018
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF TrialGene R Quinn, Anne S Hellkamp, Graeme J Hankey, et al.
Journal of Thrombosis and Thrombolysis|July 28, 2018
Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryLarry R Jackson, Sunghee Kim, Peter Shrader, et al.
American Heart Journal|September 29, 2014
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)William Schuyler Jones, Pierluigi Tricoci, Zhen Huang, et al.
Circulation|December 18, 2015
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial FibrillationJonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
European Heart Journal|September 25, 2015
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIXJ Antonio Gutierrez, Robert A Harrington, James C Blankenship, et al.
Circulation. Cardiovascular Interventions|December 17, 2021
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIXMatthew A Cavender, Robert A Harrington, Gregg W Stone, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 8, 2021
Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney DiseaseSimke W Waijer, Taha Sen, Clare Arnott, et al.
American Heart Journal Plus : Cardiology Research and Practice|March 29, 2024
Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention - Insights from the CHAMPION programJ Antonio Gutierrez, Robert A Harrington, Gregg W Stone, et al.
Journal of the American Heart Association|May 23, 2024
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF AnalysisJosephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Journal of the American Heart Association|March 26, 2013
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trialDaniel E Singer, Anne S Hellkamp, Jonathan P Piccini, et al.
Pageof 64

Showing results (401-410 of 635) with videos related to

Sort By:
Pageof 64
Journal of the American Heart Association|October 30, 2018
Selective Serotonin Reuptake Inhibitors and Bleeding Risk in Anticoagulated Patients With Atrial Fibrillation: An Analysis From the ROCKET AF TrialGene R Quinn, Anne S Hellkamp, Graeme J Hankey, et al.
Journal of Thrombosis and Thrombolysis|July 28, 2018
Early therapeutic persistence on dabigatran versus warfarin therapy in patients with atrial fibrillation: results from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) registryLarry R Jackson, Sunghee Kim, Peter Shrader, et al.
American Heart Journal|September 29, 2014
Vorapaxar in patients with peripheral artery disease and acute coronary syndrome: insights from Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER)William Schuyler Jones, Pierluigi Tricoci, Zhen Huang, et al.
Circulation|December 18, 2015
Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial FibrillationJonathan P Piccini, Anne S Hellkamp, Jeffrey B Washam, et al.
European Heart Journal|September 25, 2015
The effect of cangrelor and access site on ischaemic and bleeding events: insights from CHAMPION PHOENIXJ Antonio Gutierrez, Robert A Harrington, James C Blankenship, et al.
Circulation. Cardiovascular Interventions|December 17, 2021
Ischemic Events Occur Early in Patients Undergoing Percutaneous Coronary Intervention and Are Reduced With Cangrelor: Findings From CHAMPION PHOENIXMatthew A Cavender, Robert A Harrington, Gregg W Stone, et al.
Clinical Journal of the American Society of Nephrology : CJASN|December 8, 2021
Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney DiseaseSimke W Waijer, Taha Sen, Clare Arnott, et al.
American Heart Journal Plus : Cardiology Research and Practice|March 29, 2024
Efficacy and safety of cangrelor in patients with peripheral artery disease undergoing percutaneous coronary intervention - Insights from the CHAMPION programJ Antonio Gutierrez, Robert A Harrington, Gregg W Stone, et al.
Journal of the American Heart Association|May 23, 2024
Assessment of Days Alive Out of Hospital as a Possible End Point in Trials of Stroke Prevention for Atrial Fibrillation: A ROCKET AF AnalysisJosephine Harrington, Anne S Hellkamp, Kenneth W Mahaffey, et al.
Journal of the American Heart Association|March 26, 2013
Impact of global geographic region on time in therapeutic range on warfarin anticoagulant therapy: data from the ROCKET AF clinical trialDaniel E Singer, Anne S Hellkamp, Jonathan P Piccini, et al.
Pageof 64